CA-COGNIGY
22.10.2020 11:02:10 CEST | Business Wire | Press release
Cognigy , a global leader in Conversational AI, today announced the release of Cognigy Voice Gateway (VG), an artificial intelligence voice solution, which deploys virtual agents (naturally-conversing voice bots) for automated inbound and outbound voice calls, whether via phone, web or mobile. Cognigy VG is designed to empower enterprises to automate high volume customer support requests and deliver high-quality, personalized experiences at scale on any channel and in any language.
In 2020, customer service teams in every industry have faced unprecedented issues that have led to staff cuts, workload distribution problems and more. Call centers have struggled with low satisfaction rates for years, due to long IVR menus, extended wait times, poor NLUs to solve customer problems, narrow channel options, and an overall lag in technological advancement.
Cognigy VG is a comprehensive solution that addresses these gaps. An enterprise-ready, AI-based Conversational IVR solution, it can deploy virtual voice agents, co-exist with existing technology, and enhance the work of human agents. With its advanced multi-tasking capabilities, Cognigy VG can handle thousands of parallel AI-phone calls with live audio streams in near-real-time. To ensure 24x7 operation along with integrity, redundant configurations with underlying voice gateway instances are available.
“Voice-based AI is the future of Customer Service and CX,” said Philipp Heltewig, CEO and co-founder of Cognigy. “Customer service teams have been overwhelmed throughout the pandemic, and we are leading the automation of conversations to make life easier for everyone. Cognigy Voice Gateway is now helping our global customers respond to pressures by scaling to demand, reducing call resolution times, and overcoming other major challenges, which is driving up satisfaction on many fronts.”
Highlights of Cognigy Voice Gateway:
- Intelligent conversational skills: Understands, interprets and analyzes voice calls to appropriately respond in human-like speech.
- Advanced technology: Employs next-generation AI technologies, including Machine Learning (ML), Natural Language Processing (NLP), Natural Language Generation, Sentiment Analysis, and Speech Recognition to provide the best quality output.
- Multi-tasking: Handles thousands of calls simultaneously and makes routine problem-solving easier and quicker for callers.
- Assistance to live agents : Speeds up routine calls, smoothly transferring calls to a live agent when an interaction requires human intervention.
- Security: Enterprise-grade security, GDPR privacy, compliance resilience and availability.
Listen to a sample automated phone interaction and learn more about Cognigy Voice Gateway at https://www.cognigy.com/products/voice-gateway .
About Cognigy
Cognigy is a global leader in Conversational AI Automation. Its platform, Cognigy.AI, enables enterprises to automate customer and employee communications using intelligent voice- and chatbots. With precise, reliable intent recognition, highly flexible dialogs and seamless integration into backend systems, Cognigy.AI creates superior user experiences and helps companies reduce Support costs and increase efficiency. Cognigy.AI is available in SaaS and on-premise environments and supports conversations in any language and on any channel including web, phone, SMS and mobile apps. Cognigy’s worldwide client portfolio includes Daimler, Bosch, Lufthansa, Salzburg AG and many more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005008/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom